MX302718B - Derivado de carbamoilpiridona policiclico que tiene actividad inhibidora de la integrasa de hiv. - Google Patents

Derivado de carbamoilpiridona policiclico que tiene actividad inhibidora de la integrasa de hiv.

Info

Publication number
MX302718B
MX302718B MX2007013351A MX2007013351A MX302718B MX 302718 B MX302718 B MX 302718B MX 2007013351 A MX2007013351 A MX 2007013351A MX 2007013351 A MX2007013351 A MX 2007013351A MX 302718 B MX302718 B MX 302718B
Authority
MX
Mexico
Prior art keywords
inhibitory activity
hiv integrase
integrase inhibitory
polycyclic carbamoylpyridone
carbamoylpyridone derivative
Prior art date
Application number
MX2007013351A
Other languages
English (en)
Spanish (es)
Other versions
MX2007013351A (es
Inventor
Brian Alvin Johns
Takashi Kawasuji
Teruhiko Taishi
Yoshiyuki Taoda
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37215098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX302718(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MX2007013351A publication Critical patent/MX2007013351A/es
Publication of MX302718B publication Critical patent/MX302718B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MX2007013351A 2005-04-28 2006-04-28 Derivado de carbamoilpiridona policiclico que tiene actividad inhibidora de la integrasa de hiv. MX302718B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2005131161 2005-04-28
JP2005312076 2005-10-27
PCT/US2006/016604 WO2006116764A1 (en) 2005-04-28 2006-04-28 Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity

Publications (2)

Publication Number Publication Date
MX2007013351A MX2007013351A (es) 2008-01-21
MX302718B true MX302718B (es) 2012-08-27

Family

ID=37215098

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2007013351A MX302718B (es) 2005-04-28 2006-04-28 Derivado de carbamoilpiridona policiclico que tiene actividad inhibidora de la integrasa de hiv.
MX2011010484A MX312216B (en) 2005-04-28 2007-10-25 Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2011010484A MX312216B (en) 2005-04-28 2007-10-25 Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity

Country Status (29)

Country Link
US (22) US8129385B2 (enrdf_load_stackoverflow)
EP (9) EP1874117B8 (enrdf_load_stackoverflow)
JP (2) JP4295353B2 (enrdf_load_stackoverflow)
KR (4) KR101363875B1 (enrdf_load_stackoverflow)
AU (1) AU2006239177B8 (enrdf_load_stackoverflow)
BR (1) BRPI0610030B8 (enrdf_load_stackoverflow)
CA (1) CA2606282C (enrdf_load_stackoverflow)
CY (7) CY1115151T1 (enrdf_load_stackoverflow)
DK (6) DK2465580T3 (enrdf_load_stackoverflow)
EA (1) EA014162B1 (enrdf_load_stackoverflow)
ES (7) ES2446324T3 (enrdf_load_stackoverflow)
FI (1) FIC20210017I1 (enrdf_load_stackoverflow)
FR (1) FR14C0041I2 (enrdf_load_stackoverflow)
HK (2) HK1249742A1 (enrdf_load_stackoverflow)
HU (6) HUE056603T2 (enrdf_load_stackoverflow)
IL (4) IL186555A (enrdf_load_stackoverflow)
LT (4) LT3045206T (enrdf_load_stackoverflow)
LU (2) LU92446I2 (enrdf_load_stackoverflow)
MA (1) MA29460B1 (enrdf_load_stackoverflow)
MX (2) MX302718B (enrdf_load_stackoverflow)
NL (2) NL300676I2 (enrdf_load_stackoverflow)
NO (5) NO339525B1 (enrdf_load_stackoverflow)
NZ (1) NZ562339A (enrdf_load_stackoverflow)
PL (5) PL1874117T3 (enrdf_load_stackoverflow)
PT (5) PT3372281T (enrdf_load_stackoverflow)
SI (6) SI3045206T1 (enrdf_load_stackoverflow)
TW (1) TWI378931B (enrdf_load_stackoverflow)
VN (1) VN34404A1 (enrdf_load_stackoverflow)
WO (1) WO2006116764A1 (enrdf_load_stackoverflow)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2422444C2 (ru) 2003-12-24 2011-06-27 Байота Сайентифик Менеджмент Пти Лтд Полициклические средства для лечения респираторно-синцитиальных вирусных инфекций
US7273859B2 (en) * 2004-05-12 2007-09-25 Bristol-Myers Squibb Company HIV integrase inhibitors: cyclic pyrimidinone compounds
SI3045206T1 (en) 2005-04-28 2018-07-31 Viiv Healthcare Company A polycyclic carbamoylpyridone derivative with inhibitory activity for the HIV integrase
JP4982482B2 (ja) 2005-05-10 2012-07-25 メルク・シャープ・エンド・ドーム・コーポレイション Ｈｉｖインテグラ−ゼ阻害剤
ATE517899T1 (de) 2005-10-04 2011-08-15 Angeletti P Ist Richerche Bio Hiv-integrasehemmer
TW200800988A (en) * 2005-10-27 2008-01-01 Shionogi & Amp Co Ltd Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
TWI423972B (zh) 2006-09-28 2014-01-21 Biota Scient Management 治療呼吸系融合細胞病毒感染之多環劑
CN102124011A (zh) * 2007-11-15 2011-07-13 贝林格尔.英格海姆国际有限公司 人类免疫缺陷病毒复制的抑制剂
PT2220076E (pt) 2007-11-15 2012-04-26 Gilead Sciences Inc Inibidores da replicação do vírus da imunodeficiência humana
AU2008323558C1 (en) 2007-11-16 2014-05-01 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
ES2395705T3 (es) * 2008-07-25 2013-02-14 Glaxosmithkline Llc Compuestos químicos
WO2010011815A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
JP5586602B2 (ja) 2008-07-25 2014-09-10 ビーブ・ヘルスケア・カンパニー 化合物
ES2448766T3 (es) * 2008-07-25 2014-03-17 Viiv Healthcare Company Profármacos de dolutegravir
WO2010011818A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
SG171731A1 (en) 2008-12-11 2011-07-28 Glaxosmithkline Llc Processes and intermediates for carbamoylpyridone hiv integrase inhibitors
US8710249B2 (en) 2008-12-11 2014-04-29 Shionogi & Co., Ltd. Maltol ether processes and intermediates
AU2014277831C1 (en) * 2008-12-11 2022-10-06 Shionogi & Co. Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
KR101733625B1 (ko) 2008-12-11 2017-05-10 시오노기세야쿠 가부시키가이샤 카르바모일피리돈 ｈｉｖ 인테그라제 억제제 및 중간체의 합성
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
WO2010147068A1 (ja) 2009-06-15 2010-12-23 塩野義製薬株式会社 置換された多環性カルバモイルピリドン誘導体
WO2011011483A1 (en) * 2009-07-22 2011-01-27 Glaxosmithkline Llc Chemical compounds
CA2777664C (en) 2009-10-13 2014-06-10 Johannes Wilhelmus J. Thuring Macrocyclic integrase inhibitors
AU2014202405B2 (en) * 2010-01-27 2016-02-25 Viiv Healthcare Company Antiviral therapy
PL3494972T3 (pl) * 2010-01-27 2024-05-27 Viiv Healthcare Company Skojarzenie dolutegrawiru i lamiwudyny do leczenia zakażenia wirusem hiv
AU2014202404C1 (en) * 2010-01-27 2022-06-23 Viiv Healthcare Company Antiviral therapy
TWI508968B (zh) * 2010-02-08 2015-11-21 Biota Scient Management 用於治療呼吸道融合性病毒感染的化合物
WO2011105590A1 (ja) * 2010-02-26 2011-09-01 日本たばこ産業株式会社 １，３，４，８－テトラヒドロ－２Ｈ－ピリド［１，２－ａ］ピラジン誘導体及びそのＨＩＶインテグラーゼ阻害剤としての利用
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
CN102958935B (zh) 2010-04-02 2015-12-09 爱尔兰詹森科学公司 大环整合酶抑制剂
WO2011129095A1 (ja) * 2010-04-12 2011-10-20 塩野義製薬株式会社 インテグラーゼ阻害活性を有するピリドン誘導体
US9073941B2 (en) 2010-06-28 2015-07-07 Academia Sinica Compounds and methods for treating tuberculosis infection
SG187683A1 (en) 2010-08-05 2013-03-28 Shionogi & Co Process for preparing compound having hiv integrase inhibitory activity
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
BR112013006722B1 (pt) * 2010-09-24 2020-11-03 Shionogi & Co., Ltd profármaco de derivado de carbamoilpiridona policíclica substituída
US8796303B2 (en) 2010-11-26 2014-08-05 Biota Scientific Management Pty Ltd. Imidazo[2,1-G][1,7]naphthyridines for treating respiratory syncytial virus infections
WO2012151361A1 (en) * 2011-05-03 2012-11-08 Concert Pharmaceuticals Inc. Carbamoylpyridone derivatives
PL2742051T3 (pl) 2011-09-14 2017-06-30 Mapi Pharma Limited Amorficzna postać soli sodowej dolutegrawiru
EP2774928B1 (en) 2011-10-12 2017-08-30 Shionogi & Co., Ltd. Polycyclic pyridone derivative having integrase-inhibiting activity
SI3141542T1 (sl) 2011-12-28 2020-11-30 Global Blood Therapeutics, Inc. Substituirane spojine benzaldehida in metode njihove uporabe pri povečanju oksigenacije tkiva
EP2797597B1 (en) 2011-12-28 2020-02-26 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
EP2931730B1 (en) * 2012-12-17 2019-08-07 Merck Sharp & Dohme Corp. 4-pyridinonetriazine derivatives as hiv integrase inhibitors
SI3608325T1 (sl) * 2012-12-21 2022-09-30 Gilead Sciences, Inc. Policiklične-karbamoilpiridonske spojine in njihova farmacevtska uporaba
PE20151063A1 (es) * 2012-12-27 2015-08-03 Japan Tobacco Inc DERIVADO SUSTITUIDO DE ESPIROPIRIDO[1,2-a]PIRAZINA Y USO MEDICO DEL MISMO COMO INHIBIDOR DE LA INTEGRASA DEL VIH
EP2767272A1 (en) 2013-02-18 2014-08-20 Ratiopharm GmbH Solid pharmaceutical dosage form of dolutegravir
WO2014125124A1 (en) 2013-02-18 2014-08-21 Ratiopharm Gmbh Solid pharmaceutical dosage form of dolutegravir
WO2014128545A2 (en) 2013-02-19 2014-08-28 Aurobindo Pharma Limited An improved process for the preparation of dolutegravir
US9604999B2 (en) 2013-03-15 2017-03-28 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EP2968299B1 (en) 2013-03-15 2021-01-20 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014150268A1 (en) 2013-03-15 2014-09-25 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SG11201507349TA (en) 2013-03-15 2015-10-29 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
EP2986291B1 (en) 2013-04-16 2020-05-27 Merck Sharp & Dohme Corp. 4-pyridone derivative compounds and uses thereof as hiv integrase inhibitors
US9951079B2 (en) * 2013-06-13 2018-04-24 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds as HIV integrase inhibitors
EP3016935B1 (en) * 2013-07-04 2018-09-05 Hetero Research Foundation Process for the preparation of intermediate of dolutegravir
ES2859102T3 (es) * 2013-07-12 2021-10-01 Gilead Sciences Inc Compuestos de carbamoilpiridona policíclica y su uso para el tratamiento de infecciones por VIH
NO2865735T3 (enrdf_load_stackoverflow) * 2013-07-12 2018-07-21
US9856270B2 (en) 2013-07-17 2018-01-02 Ratiopharm Gmbh Dolutegravir salts
WO2015019310A1 (en) 2013-08-07 2015-02-12 Mylan Laboratories Ltd Process for the preparation of dolute-gravir and intermediates thereof
WO2015039348A1 (en) * 2013-09-23 2015-03-26 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
CN105744936B (zh) * 2013-09-27 2019-07-30 默沙东公司 可用作hiv整合酶抑制剂的取代喹嗪衍生物
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
WO2015092752A1 (en) 2013-12-20 2015-06-25 Mylan Laboratories Ltd. Novel crystalline form of dolutegravir sodium
WO2015089847A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Spirocyclic heterocycle compounds useful as hiv integrase inhibitors
US9808428B2 (en) 2014-01-14 2017-11-07 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
IN2014CH00247A (enrdf_load_stackoverflow) 2014-01-21 2015-08-14 Laurus Labs Private Ltd
ES2860648T5 (es) 2014-02-07 2024-11-27 Global Blood Therapeutics Inc Polimorfos cristalinos de la base libre de 2-hidroxi-6-((2-(1-isopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehído
WO2015138933A1 (en) 2014-03-13 2015-09-17 Assia Chemical Industries Ltd. Solid state forms of dolutegravir sodium
CN105121409B (zh) * 2014-03-19 2017-05-24 杭州普晒医药科技有限公司 德罗格韦钠盐的晶型及其制备方法
IN2014MU00916A (enrdf_load_stackoverflow) 2014-03-20 2015-09-25 Cipla Ltd
WO2015177537A1 (en) * 2014-05-20 2015-11-26 Cipla Limited Process for preparing polycyclic carbamoyl pyridone derivatives and intermediates thereof
NO2717902T3 (enrdf_load_stackoverflow) * 2014-06-20 2018-06-23
TWI677489B (zh) * 2014-06-20 2019-11-21 美商基利科學股份有限公司 多環型胺甲醯基吡啶酮化合物之合成
TW201613936A (en) * 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
JPWO2016027879A1 (ja) 2014-08-22 2017-06-01 塩野義製薬株式会社 インテグラーゼ阻害活性を有する多環性ピリドン誘導体
WO2016057866A1 (en) 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
WO2016092527A1 (en) * 2014-12-12 2016-06-16 Sun Pharmaceutical Industries Limited A process for the preparation of dolutegravir
TWI695003B (zh) 2014-12-23 2020-06-01 美商基利科學股份有限公司 多環胺甲醯基吡啶酮化合物及其醫藥用途
EP3045461A1 (en) 2015-01-16 2016-07-20 LEK Pharmaceuticals d.d. Processes for preparing dolutegravir and analogues thereof
US10730888B2 (en) 2015-02-06 2020-08-04 Mylan Laboratories Limited Process for the preparation of dolutegravir
CZ201599A3 (cs) 2015-02-13 2016-08-24 Zentiva, K.S. Pevné formy solí dolutegraviru a způsob jejich přípravy
US10081647B2 (en) * 2015-03-26 2018-09-25 Merck Sharp & Dohme Corp. Phosphate substituted quinolizine derivatives useful as HIV integrase inhibitors
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
CN107531727B (zh) * 2015-04-02 2019-11-29 吉利德科学公司 多环氨甲酰基吡啶酮化合物及其药物用途
BR112017022550B1 (pt) * 2015-04-28 2021-02-23 Shionogi & Co., Ltd derivados policíclicos de piridona substituída
WO2016187788A1 (en) 2015-05-25 2016-12-01 Merck Sharp & Dohme Corp. Fused tricyclic heterocyclic compounds useful for treating hiv infection
CZ2015537A3 (cs) 2015-08-04 2017-02-15 Zentiva, K.S. Pevné formy amorfního dolutegraviru
EP3337479B1 (en) 2015-08-19 2023-12-13 Laurus Labs Limited Novel polymorphs of dolutegravir and salts thereof
SG11201802983TA (en) 2015-11-09 2018-05-30 Gilead Sciences Inc Therapeutic compositions for treatment of human immunodeficiency virus
WO2017087257A1 (en) 2015-11-17 2017-05-26 Merck Sharp & Dohme Corp. Amido-substituted pyridotriazine derivatives useful as hiv integrase inhibitors
SG10201912511WA (en) 2015-12-04 2020-02-27 Global Blood Therapeutics Inc Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
WO2017106071A1 (en) 2015-12-15 2017-06-22 Merck Sharp & Dohme Corp. Spirocyclic quinolizine derivatives useful as hiv integrase inhibitors
EP3394069B1 (en) 2015-12-21 2019-05-22 Lupin Limited Process for the preparation of hiv integrase inhibitors
AR108435A1 (es) 2016-05-12 2018-08-22 Global Blood Therapeutics Inc Proceso para sintetizar 2-hidroxi-6-((2-(1-isopropil-1h-pirazol-5-il)-piridin-3-il)metoxi)benzaldehído
WO2017208105A1 (en) 2016-05-30 2017-12-07 Lupin Limited Novel crystalline form of dolutegravir sodium
EP4299133A3 (en) * 2016-06-23 2024-03-13 VIIV Healthcare Company Compositions and methods for the delivery of therapeutics
ES2952878T3 (es) 2016-08-08 2023-11-06 Hetero Labs Ltd Una composición antirretroviral multiclase
BR112019002132A2 (pt) 2016-08-08 2019-05-14 Hetero Labs Limited composições anti-retrovirais
CN109789144B (zh) * 2016-08-12 2022-04-15 马德拉医疗公司 蛋白激酶调节剂
WO2018042332A1 (en) 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
US20190216725A1 (en) * 2016-09-21 2019-07-18 Merck Shapr & Dohme Corp. Drug delivery system for the delivery of integrase inhibitors
TW202332423A (zh) 2016-10-12 2023-08-16 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
JOP20190130A1 (ar) * 2016-12-02 2019-06-02 Merck Sharp & Dohme مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv)
EP3548031B1 (en) 2016-12-02 2023-07-19 Merck Sharp & Dohme LLC Tricyclic heterocycle compounds useful as hiv integrase inhibitors
WO2018109786A1 (en) 2016-12-16 2018-06-21 Cipla Limited Novel polymoprphs and salts of polycyclic carbamoyl pyridone derivatives
US10786488B2 (en) 2017-01-26 2020-09-29 Merck Sharp & Dohme Corp. Substituted quinolizine derivatives useful as HIV integrase inhibitors
EP3363802B1 (en) 2017-02-16 2019-11-20 Sandoz AG Crystalline form of cabotegravir sodium
MX388699B (es) 2017-02-16 2025-03-20 Viiv Healthcare Uk No 3 Ltd Formas cristalinas de cabotegravir de sodio
WO2019016679A1 (en) * 2017-07-18 2019-01-24 Viiv Healthcare Company COMBINATION THERAPY
WO2019016732A1 (en) 2017-07-21 2019-01-24 Viiv Healthcare Company Regimens for treating hib infections and aids
WO2019048808A1 (en) 2017-09-07 2019-03-14 Cipla Limited NOVEL POLYMORPHS OF DOLUTÉGRAVIR SODIQUE
MX2020003469A (es) 2017-10-06 2020-08-03 Shionogi & Co Proceso estereoselectivo para preparar derivados de piridona policiclicos sustituidos.
CA3126348A1 (en) 2018-01-12 2020-07-18 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and formulations thereof
WO2019159199A1 (en) 2018-02-16 2019-08-22 Cipla Limited Continues flow process for the preparation of active pharmaceutical ingredients - polycyclic carbamoyl pyridone derivatives and intermediates thereof
CA3132832A1 (en) 2018-04-09 2019-10-17 Howard E. Gendelman Antiviral prodrugs and formulations thereof
CN110526930B (zh) 2018-05-23 2022-06-03 莫云芬 抗hiv病毒的含硫多环-羟基吡啶酮甲酰胺类似物及其应用
TWI820141B (zh) * 2018-05-31 2023-11-01 日商鹽野義製藥股份有限公司 衍生物
KR102770090B1 (ko) * 2018-05-31 2025-02-18 시오노기 앤드 컴파니, 리미티드 다환성 피리돈 유도체
PE20210477A1 (es) * 2018-05-31 2021-03-11 Shionogi & Co Derivado policiclico de carbamoilpiridona
EP3820875B1 (en) 2018-07-12 2024-01-17 Laurus Labs Limited A process for purification of protected polycyclic carbamoylpyridone derivatives
EP3860975B1 (en) 2018-10-01 2023-10-18 Global Blood Therapeutics, Inc. Modulators of hemoglobin for the treatment of sickle cell disease
CA3117453A1 (en) 2018-10-22 2020-04-30 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and nanoformulations thereof
WO2020112931A1 (en) 2018-11-29 2020-06-04 Board Of Regents Of The University Of Nebraska Antiviral prodrugs and nanoformulations thereof
SG11202109650XA (en) 2019-03-22 2021-10-28 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
RU2717101C1 (ru) * 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
US20200398978A1 (en) 2019-06-20 2020-12-24 Bell Helicopter Textron Inc. Low-drag rotor blade extension
US11248005B2 (en) 2019-07-08 2022-02-15 Lupin Limited Process for preparation of intermediates used for the synthesis of HIV integrase inhibitor
WO2021107066A1 (ja) 2019-11-28 2021-06-03 塩野義製薬株式会社 インテグラーゼ阻害剤及び抗ｈｉｖ薬を組み合わせることを特徴とするｈｉｖ感染症の予防及び治療用医薬
CA3164528A1 (en) 2019-12-09 2021-06-17 Viiv Healthcare Company Pharmaceutical compositions comprising cabotegravir
MX2022009871A (es) 2020-02-24 2022-08-19 Gilead Sciences Inc Compuestos tetraciclicos para tratar la infeccion por el virus de la inmunodeficiencia humana (vih).
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
JP2023539344A (ja) 2020-09-01 2023-09-13 ヴィーブ、ヘルスケア、カンパニー カボテグラビルおよびレボノルゲストレルの組合せ
WO2022079739A1 (en) 2020-10-14 2022-04-21 Cipla Limited Fixed dose compositions of cabotegravir and rilpivirine
WO2022125378A2 (en) 2020-12-07 2022-06-16 Viiv Healthcare Company Combination therapy
CR20230315A (es) 2021-01-19 2023-09-01 Gilead Sciences Inc Compuestos de piridotriazina sustituidos y usos de estos
EP4389745A1 (en) 2021-06-03 2024-06-26 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pyridone compound having integrase inhibitory activity and pharmaceutical use thereof
CN114230579A (zh) * 2021-11-12 2022-03-25 南京艾迪医药科技有限公司 多环氨基甲酰基吡啶酮衍生物及其制备方法和药物组合物
WO2023102374A1 (en) 2021-12-03 2023-06-08 Viiv Healthcase Company Process of synthesizing (r)-3-aminobutan-1-ol
TW202446773A (zh) 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024153203A1 (en) * 2023-01-18 2024-07-25 Ascletis BioScience Co., Ltd Integrase inhibitor and use thereof
WO2025068743A1 (en) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
WO2025068912A1 (en) 2023-09-27 2025-04-03 ViiV Healthcare UK (No.3) Limited Pharmaceutical compositions
WO2025128496A1 (en) 2023-12-12 2025-06-19 Viiv Healthcare Company Crystalline form
WO2025128498A1 (en) 2023-12-12 2025-06-19 Viiv Healthcare Company Pharmaceutical compositions

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959316A (en) * 1972-03-13 1976-05-25 Snam Progetti S.P.A. Procedure for propylene oxide synthesis
JPH0296506A (ja) 1988-09-30 1990-04-09 Daicel Chem Ind Ltd 除草剤組成物
JP2551472B2 (ja) 1988-10-18 1996-11-06 ダイセル化学工業株式会社 ５−アルコキシ−γ−ピロン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
JP2533796B2 (ja) 1988-10-18 1996-09-11 ダイセル化学工業株式会社 ５−アルコキシピリジン−３−カルボキサミド誘導体とその製造方法及び植物成長抑制剤
AU755707B2 (en) 1997-12-22 2002-12-19 Pharmacia & Upjohn Company 4-hydroxyquinoline-3-carboxamides and hydrazides as antiviral agents
US20040039060A1 (en) † 2000-06-14 2004-02-26 Ryuichi Kiyama Inhibitor for enzyme having two divalent metal ions as active centers
US6580562B2 (en) 2000-07-24 2003-06-17 Yazaki Corporation On-vehicle display unit
US6384263B1 (en) 2000-08-04 2002-05-07 E. I. Du Pont De Nemours And Company Process for making 3-hydroxyalkanelnitriles and conversion of the 3-hydroxyalkanelnitrile to an hydroxyaminoalkane
JP4287649B2 (ja) 2000-10-12 2009-07-01 メルク エンド カムパニー インコーポレーテッド Ｈｉｖインテグラーゼ阻害薬として有用なアザ−およびポリアザ−ナフタレニルカルボキサミド類
JP2003032772A (ja) 2001-07-12 2003-01-31 Foster Electric Co Ltd 耳掛け式イヤホン
JP4338192B2 (ja) 2001-08-10 2009-10-07 塩野義製薬株式会社 抗ウイルス剤
PL212914B1 (pl) 2001-10-26 2012-12-31 Angeletti P Ist Richerche Bio N-podstawione hydroksypirymidynonokarboksyamidy jako inhibitory integrazy HIV
AU2002334205B2 (en) 2001-10-26 2007-07-05 Istituto Di Ricerche Di Biologia Molecolara P. Angeletti Spa Dihydroxypyrimidine carboxamide inhibitors of HIV integrase
US7279487B2 (en) 2002-01-17 2007-10-09 Merck & Co., Inc. Hydroxynaphthyridinone carboxamides useful as HIV integrase inhibitors
AU2003248872A1 (en) 2002-07-09 2004-01-23 Bristol-Myers Squibb Company Hiv integrase inhibitors
ATE404537T1 (de) 2002-08-13 2008-08-15 Shionogi & Co Heterocyclische verbindungen mit hiv-integrase- hemmender wirkung
JP2006506352A (ja) 2002-09-11 2006-02-23 メルク　エンド　カムパニー　インコーポレーテッド Ｈｉｖインテグラーゼ阻害剤として有用なジヒドロキシピリドピラジン−１，６−ジオン化合物
DE60334248D1 (de) 2002-12-27 2010-10-28 Angeletti P Ist Richerche Bio Tetrahydro-4h-pyridoä1,2-aüpyrimidine und verwandte verbindungen verwendbar als hiv integrase hemmer
US6960680B2 (en) 2003-01-08 2005-11-01 Rhodia Chirex, Inc. Manufacture of water-soluble β-hydroxynitriles
JP2004244320A (ja) 2003-02-10 2004-09-02 Shionogi & Co Ltd 含窒素複素環抗ウイルス剤
JP2006528694A (ja) 2003-05-13 2006-12-21 スミスクライン ビーチャム コーポレーション ナフチリジンインテグラーゼインヒビター
AU2003273190A1 (en) * 2003-08-12 2005-02-25 Rachel Beijer Scheduled message service
TW200510425A (en) † 2003-08-13 2005-03-16 Japan Tobacco Inc Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor
JP4530642B2 (ja) 2003-10-31 2010-08-25 オリンパス株式会社 内視鏡装置
ES2433477T3 (es) 2004-02-11 2013-12-11 Glaxosmithkline Llc Inhibidores de integrasa de VIH
WO2005087766A1 (en) 2004-03-09 2005-09-22 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Hiv integrase inhibitors
CN1929737A (zh) † 2004-03-09 2007-03-14 默克公司 Hiv整合酶抑制剂
ES2529038T3 (es) 2004-05-07 2015-02-16 Merck Sharp & Dohme Corp. Inhibidores de la integrasa de VIH
EP1973906A1 (en) 2004-12-23 2008-10-01 Virochem Pharma Inc. Hydroxydihydropyridopy razine-1,8-diones and methods for inhibiting hiv integrase
EP1852434B1 (en) * 2005-02-21 2011-07-13 Shionogi Co., Ltd. Bicyclic carbamoylpyridone derivative having hiv integrase inhibiting activity
CN101146811B (zh) 2005-03-31 2012-01-11 P.安杰莱蒂分子生物学研究所 Hiv整合酶抑制剂
SI3045206T1 (en) * 2005-04-28 2018-07-31 Viiv Healthcare Company A polycyclic carbamoylpyridone derivative with inhibitory activity for the HIV integrase
JP2005312076A (ja) 2005-05-26 2005-11-04 Olympus Corp 電子撮像装置
US20080214527A1 (en) 2005-08-04 2008-09-04 Takashi Kawasuji Hiv Integrase Inhibitors
TW200800988A (en) 2005-10-27 2008-01-01 Shionogi & Amp Co Ltd Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity

Also Published As

Publication number Publication date
US10927129B2 (en) 2021-02-23
US20170369509A1 (en) 2017-12-28
KR20160003889A (ko) 2016-01-11
DK3284520T3 (da) 2019-09-16
KR101848819B1 (ko) 2018-04-16
US20140200209A1 (en) 2014-07-17
KR101363875B1 (ko) 2014-02-21
CY1124601T1 (el) 2022-07-22
HK1249742A1 (en) 2018-11-09
EP3045206A1 (en) 2016-07-20
NO2017010I1 (no) 2017-03-27
SI3187225T1 (sl) 2022-04-29
NZ562339A (en) 2011-01-28
AU2006239177A1 (en) 2006-11-02
IL186555A0 (en) 2008-01-20
US20120115875A1 (en) 2012-05-10
HUE056603T2 (hu) 2022-02-28
HUE044978T2 (hu) 2019-11-28
US20090318421A1 (en) 2009-12-24
US20160304535A1 (en) 2016-10-20
AU2006239177B2 (en) 2011-10-20
EP2465580A1 (en) 2012-06-20
PL1874117T3 (pl) 2014-01-31
US20170260203A1 (en) 2017-09-14
SI3372281T1 (sl) 2021-11-30
NO340111B1 (no) 2017-03-13
US9051337B2 (en) 2015-06-09
US20170145033A1 (en) 2017-05-25
TWI378931B (en) 2012-12-11
LU92446I2 (fr) 2015-10-29
FIC20210017I1 (fi) 2021-06-10
US20220213121A1 (en) 2022-07-07
PT2465580E (pt) 2014-02-25
ES2906792T3 (es) 2022-04-20
FR14C0041I1 (enrdf_load_stackoverflow) 2014-06-27
US8410103B2 (en) 2013-04-02
HUS1400039I1 (hu) 2016-08-29
EP1874117B1 (en) 2013-08-28
EP3187225B1 (en) 2022-01-05
US20160207939A1 (en) 2016-07-21
ES2892304T3 (es) 2022-02-03
MA29460B1 (fr) 2008-05-02
HUS2100022I1 (hu) 2021-07-28
CY1116331T1 (el) 2017-02-08
EP3284520B1 (en) 2019-06-05
CY2014024I1 (el) 2015-12-09
EP3372281B1 (en) 2021-07-07
VN34404A1 (en) 2013-07-25
ES2567197T3 (es) 2016-04-20
EA014162B1 (ru) 2010-10-29
KR20140097438A (ko) 2014-08-06
KR20130133061A (ko) 2013-12-05
EP1874117B8 (en) 2014-03-12
SI1874117T1 (sl) 2014-01-31
JP4295353B2 (ja) 2009-07-15
IL186555A (en) 2016-10-31
EP2527007A1 (en) 2012-11-28
BRPI0610030A2 (pt) 2011-10-11
CY1115151T1 (el) 2015-12-09
US20190284208A1 (en) 2019-09-19
PL3372281T3 (pl) 2021-12-27
US20170029438A1 (en) 2017-02-02
EP2527007B1 (en) 2016-03-30
EP3187226A1 (en) 2017-07-05
LT3284520T (lt) 2019-09-25
ES2743531T3 (es) 2020-02-19
DK1874117T3 (da) 2013-09-23
NO339525B1 (no) 2016-12-27
US20200339598A1 (en) 2020-10-29
US20150232479A1 (en) 2015-08-20
EP3372281A1 (en) 2018-09-12
CY1120345T1 (el) 2019-07-10
EA200702080A1 (ru) 2008-04-28
SI2465580T1 (sl) 2014-04-30
US20160137666A1 (en) 2016-05-19
EP1874117A1 (en) 2008-01-09
TW200716635A (en) 2007-05-01
EP3284519A1 (en) 2018-02-21
CY1122052T1 (el) 2020-10-14
US8778943B2 (en) 2014-07-15
PL2465580T3 (pl) 2014-05-30
SI3284520T1 (sl) 2019-10-30
NO2021018I1 (no) 2021-05-10
ES2667868T5 (es) 2023-06-01
KR20080009733A (ko) 2008-01-29
LT3045206T (lt) 2018-06-11
JP2008540343A (ja) 2008-11-20
IL215788A0 (en) 2011-12-29
IL225206A (en) 2017-11-30
SI3045206T1 (en) 2018-07-31
LT3372281T (lt) 2021-12-10
NL301109I2 (nl) 2021-09-15
US20130172559A1 (en) 2013-07-04
EP1874117A4 (en) 2009-12-30
EP3284520A1 (en) 2018-02-21
NO2017010I2 (no) 2017-03-27
ES2667868T3 (es) 2018-05-14
LTC2465580I2 (enrdf_load_stackoverflow) 2022-10-10
CY2021016I2 (el) 2021-12-31
PT3284520T (pt) 2019-09-10
US20240279238A1 (en) 2024-08-22
EP3045206B2 (en) 2023-02-15
NO2023042I1 (no) 2023-11-08
IL225207A (en) 2017-11-30
EP3284519A8 (en) 2018-04-18
US20170224694A1 (en) 2017-08-10
DK3187225T3 (da) 2022-02-28
US20170209454A1 (en) 2017-07-27
HUS2100023I1 (hu) 2021-07-28
CA2606282C (en) 2016-04-26
NO20075165L (no) 2007-11-22
US20170267693A1 (en) 2017-09-21
MX2007013351A (es) 2008-01-21
DK3372281T3 (da) 2021-09-27
PT1874117E (pt) 2013-10-17
LTPA2021512I1 (enrdf_load_stackoverflow) 2021-07-12
ES2446324T3 (es) 2014-03-07
HK1172282A1 (en) 2013-04-19
NL300676I2 (enrdf_load_stackoverflow) 2016-10-11
DK2465580T3 (en) 2014-03-10
LUC00210I2 (enrdf_load_stackoverflow) 2022-10-07
US9273065B2 (en) 2016-03-01
EP2465580B1 (en) 2013-12-18
MX312216B (en) 2013-08-12
PT3045206T (pt) 2018-07-05
KR101580310B1 (ko) 2016-01-04
US20170224695A1 (en) 2017-08-10
PL3045206T3 (pl) 2018-08-31
DK3045206T3 (en) 2018-05-22
HK1107227A1 (en) 2008-04-03
WO2006116764A1 (en) 2006-11-02
PT3372281T (pt) 2021-10-14
NO20161315A1 (no) 2007-11-22
US8129385B2 (en) 2012-03-06
US20170253616A1 (en) 2017-09-07
ES2437268T3 (es) 2014-01-09
KR101504998B1 (ko) 2015-03-23
HUE037795T2 (hu) 2018-09-28
JP2009079058A (ja) 2009-04-16
PL3284520T3 (pl) 2020-01-31
CA2606282A1 (en) 2006-11-02
BRPI0610030B8 (pt) 2022-01-11
AU2006239177B8 (en) 2012-02-16
CY2021016I1 (el) 2021-10-15
EP3045206B1 (en) 2018-03-28
HK1251191A1 (en) 2019-01-25
FR14C0041I2 (fr) 2015-11-13
NL301109I1 (nl) 2021-09-15
US11267823B2 (en) 2022-03-08
BRPI0610030B1 (pt) 2020-09-15
EP3187225A1 (en) 2017-07-05
US20190152990A1 (en) 2019-05-23
CY2014024I2 (el) 2025-05-09

Similar Documents

Publication Publication Date Title
MX302718B (es) Derivado de carbamoilpiridona policiclico que tiene actividad inhibidora de la integrasa de hiv.
IL190879A0 (en) Polycyclic carbamoylpyridone derivative having inhibitory activity on hiv integrase
EP1790638A4 (en) CARBAMOYLPYRIDONE DERIVATIVE HAVING INHIBITION OF HIV INTEGRASE ACTIVITY
ZA200803423B (en) Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
PL1948666T3 (pl) Inhibitory integrazy HIV
AP2383A (en) Quinoline derivatives as antibacterial agents.
EP1910363A4 (en) INHIBITORS OF HIV INTEGRASE
AP2322A (en) Antibacterial quinoline derivatives.
EP1915181A4 (en) NEW HIV TARGETS
AP2386A (en) Quinoline derivatives as antibacterial agents.
EP1910356A4 (en) HIV integrase
EP1909578A4 (en) INHIBITORS OF HIV INTEGRASE
EP1910355A4 (en) HIV integrase
GB0523781D0 (en) HIV syndrome medicine
AU2005901886A0 (en) An ophthalmoscope
ES1060100Y (es) Mueble modular.
AU2005905565A0 (en) E.U.C.G. Conveyor guarding
AU2005906280A0 (en) Budgetchoice.com
AU2005901102A0 (en) The I.D. charm

Legal Events

Date Code Title Description
HC Change of company name or juridical status
FG Grant or registration
GD Licence granted